semaglutide for heart disease GLP-1 Pill Cut Failure Events in Some Diabetes Patients The weight-loss drug Wegovy lowered

A randomized controlled trial found that carrageenan, a common food additive, may cause subclinical inflammation and insulin resistance in overweight individuals, mediated by gut permeability and inflammation

What is in the Parkinsons drug pipeline and why should folks care

Combination Therapy: While low-risk on their own, GLP-1 RAs increase hypoglycemia risk when combined with insulin or sulfonylureas

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications

Here, we explored the signaling pathway involved in the anti-apoptotic effect of GLP-1, and investigated whether metformin had an anti-apoptotic effect on beta cells

Theres not enough research to know for sure if and when its safe to take GLP-1s after giving birth